Bristol-Myers Squibb

  • Rigel and Bristol-Myers Squibb announced a research and development collaboration for TGF beta receptor kinase inhibitors for use in Immuno-Oncology related indications. (Feb 2015)

  • TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body.

  • The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors.

  • Bristol-Myers Squibb obtained exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, those which may be approved to treat cancer.